Symbols / PBM $2.46 -1.01% Psyence Biomedical Ltd.
PBM Chart
About
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.64M |
| Enterprise Value | -6.41M | Income | -3.94M | Sales | — |
| Book/sh | 39.62 | Cash/sh | 23.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.06 | P/C | — |
| EV/EBITDA | 1.55 | EV/Sales | — | Quick Ratio | 7.77 |
| Current Ratio | 8.09 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -389.98 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -34.44% |
| ROE | -74.29% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.29M |
| Shs Float | 292.59K | Short Float | 3.22% | Short Ratio | 0.34 |
| Short Interest | — | 52W High | 468.36 | 52W Low | 1.92 |
| Beta | 0.36 | Avg Volume | 198.06K | Volume | 3.87K |
| Target Price | — | Recom | None | Prev Close | $2.48 |
| Price | $2.46 | Change | -1.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.43
Latest analyst target
3. DCF / Fair value
$-31.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.43
Low
—
High
—
Mean
—
News
RSS: Latest PBM news- Inside Psyence BioMed’s debt-free push into $8.75B psychedelic drugs - Stock Titan Wed, 11 Mar 2026 07
- PBM Technical Analysis & Stock Price Forecast - Intellectia AI ue, 31 Mar 2026 09
- Bernstein upgrades Cigna stock rating on PBM reform clarity - investing.com hu, 12 Mar 2026 07
- Psyence Biomedical Ltd. Announces Delayed Implementation of 1-for-6.25 Share Consolidation Effective February 2, 2026 | PBM Stock News - Quiver Quantitative Wed, 28 Jan 2026 08
- Why Is PBM Stock Drawing So Much Investor Interest Today? - Stocktwits Mon, 02 Feb 2026 08
- CVS stock climbs 2.12% following FTC agreement, $620M trading volume places 184th amid PBM pricing reform efforts - Bitget ue, 24 Mar 2026 08
- PBM profits are obscured by accounting and mergers, USC report finds - Medical Economics Fri, 23 Jan 2026 08
- Psychedelics partner PsyLabs to own 49.98% of Psyence BioMed - Stock Titan Fri, 20 Feb 2026 08
- PBM Should I Buy - Intellectia AI Sat, 21 Mar 2026 06
- Psyence BioMed pays $1.5M to end KAOS Capital dispute - Stock Titan Wed, 11 Feb 2026 08
- Psilocybin developer’s investors back plan to combine shares up to 250-for-1 - Stock Titan ue, 17 Feb 2026 08
- Psyence BioMed shrinks share count from 6,388,604 to 1,022,177 - Stock Titan Wed, 28 Jan 2026 08
- 1-for-6.25 split leaves Psyence BioMed with 1,022,177 shares outstanding - Stock Titan Wed, 14 Jan 2026 08
- Psyence, PsyLabs deal locks in psychedelic drug supply while preserving cash - Stock Titan Fri, 13 Feb 2026 08
- Reverse stock split on hold: Psyence BioMed keeps PBM trading - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
3.66
-91.72%
|
44.23
+1267.39%
|
3.23
+74.30%
|
1.86
|
| Research And Development |
|
0.34
-64.16%
|
0.95
-40.67%
|
1.61
+1072.35%
|
0.14
|
| Selling General And Administration |
|
3.32
+84.56%
|
1.80
+10.52%
|
1.63
-5.40%
|
1.72
|
| Selling And Marketing Expense |
|
0.48
+499.89%
|
0.08
+1046.72%
|
0.01
-59.86%
|
0.02
|
| General And Administrative Expense |
|
2.83
+65.06%
|
1.72
+6.02%
|
1.62
-4.84%
|
1.70
|
| Other Gand A |
|
2.83
+65.06%
|
1.72
+6.02%
|
1.62
-4.84%
|
1.70
|
| Other Operating Expenses |
|
—
|
41.48
|
—
|
—
|
| Total Expenses |
|
3.66
-91.72%
|
44.23
+1267.39%
|
3.23
+74.30%
|
1.86
|
| Operating Income |
|
-3.66
+91.72%
|
-44.23
-1267.39%
|
-3.23
-74.30%
|
-1.86
|
| EBITDA |
|
1.03
+102.01%
|
-51.11
-1493.87%
|
-3.21
-72.76%
|
-1.86
|
| Normalized EBITDA |
|
0.50
+101.03%
|
-48.62
-1403.64%
|
-3.23
-74.43%
|
-1.85
|
| Reconciled Depreciation |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| EBIT |
|
1.02
+102.00%
|
-51.11
-1493.88%
|
-3.21
-72.76%
|
-1.86
|
| Total Unusual Items |
|
0.53
+121.10%
|
-2.49
-9346.69%
|
0.03
+1276.42%
|
-0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.53
+121.10%
|
-2.49
-9346.69%
|
0.03
+1276.42%
|
-0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-2.18
|
0.00
|
—
|
| Other Special Charges |
|
—
|
-0.28
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
2.46
|
0.00
|
—
|
| Net Income |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Pretax Income |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Net Non Operating Interest Income Expense |
|
0.09
+270.29%
|
-0.05
-3369.43%
|
0.00
|
0.00
|
| Interest Expense Non Operating |
|
0.01
-82.49%
|
0.05
|
0.00
|
—
|
| Net Interest Income |
|
0.09
+270.29%
|
-0.05
-3369.43%
|
0.00
|
0.00
|
| Interest Expense |
|
0.01
-82.49%
|
0.05
|
0.00
|
—
|
| Interest Income Non Operating |
|
0.10
+4388.61%
|
0.00
+37.32%
|
0.00
|
0.00
|
| Interest Income |
|
0.10
+4388.61%
|
0.00
+37.32%
|
0.00
|
0.00
|
| Other Income Expense |
|
4.59
+166.74%
|
-6.87
-25645.52%
|
0.03
+1276.42%
|
-0.00
|
| Other Non Operating Income Expenses |
|
4.06
+192.63%
|
-4.39
|
—
|
—
|
| Gain On Sale Of Security |
|
0.53
+269.97%
|
-0.31
-1247.98%
|
0.03
+1276.42%
|
-0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.08
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Net Income From Continuing Operation Net Minority Interest |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Net Income From Continuing And Discontinued Operation |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Net Income Continuous Operations |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Normalized Income |
|
0.57
+101.16%
|
-48.67
-1405.28%
|
-3.23
-74.21%
|
-1.86
|
| Net Income Common Stockholders |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Diluted EPS |
|
261.02
+101.83%
|
-14,274.29
-1418.51%
|
-940.02
-72.55%
|
-544.78
|
| Basic EPS |
|
261.02
+101.83%
|
-14,274.29
-1418.51%
|
-940.02
-72.55%
|
-544.78
|
| Basic Average Shares |
|
0.00
+8.12%
|
0.00
+5.07%
|
0.00
+0.00%
|
0.00
|
| Diluted Average Shares |
|
0.00
+8.12%
|
0.00
+5.07%
|
0.00
+0.00%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Depreciation Amortization Depletion Income Statement |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Depreciation Income Statement |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.32
+546.23%
|
1.13
-28.81%
|
1.59
-13.20%
|
1.83
|
| Current Assets |
|
6.56
+482.27%
|
1.13
-29.15%
|
1.59
-13.20%
|
1.83
|
| Cash Cash Equivalents And Short Term Investments |
|
6.14
+736.78%
|
0.73
-45.05%
|
1.33
-23.79%
|
1.75
|
| Cash And Cash Equivalents |
|
6.14
+736.78%
|
0.73
-45.05%
|
1.33
-23.79%
|
1.75
|
| Cash Financial |
|
6.14
+736.78%
|
0.73
-45.05%
|
1.33
-23.79%
|
1.75
|
| Receivables |
|
0.14
+229.00%
|
0.04
-72.05%
|
0.15
+277.71%
|
0.04
|
| Other Receivables |
|
0.14
+229.00%
|
0.04
-72.05%
|
0.15
+277.71%
|
0.04
|
| Prepaid Assets |
|
0.25
-21.83%
|
0.32
+318.07%
|
0.08
+1329.54%
|
0.01
|
| Restricted Cash |
|
0.04
+21.45%
|
0.03
+0.19%
|
0.03
-18.41%
|
0.04
|
| Total Non Current Assets |
|
0.76
+13679.77%
|
0.01
|
0.00
|
0.00
|
| Net PPE |
|
0.01
+102.22%
|
0.01
|
0.00
|
—
|
| Gross PPE |
|
0.02
+172.46%
|
0.01
|
0.00
|
—
|
| Accumulated Depreciation |
|
-0.00
-1778.33%
|
-0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
0.02
+172.46%
|
0.01
|
—
|
—
|
| Other Properties |
|
—
|
0.01
|
—
|
—
|
| Investments And Advances |
|
0.74
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
0.59
-95.09%
|
12.10
+575.98%
|
1.79
+1259.04%
|
0.13
|
| Current Liabilities |
|
0.59
-95.09%
|
12.10
+575.98%
|
1.79
+1259.04%
|
0.13
|
| Payables And Accrued Expenses |
|
0.31
-54.61%
|
0.69
-61.56%
|
1.79
+1259.04%
|
0.13
|
| Payables |
|
0.26
-53.42%
|
0.56
-65.46%
|
1.63
+4313.67%
|
0.04
|
| Accounts Payable |
|
0.26
-53.42%
|
0.56
-65.46%
|
1.63
+4313.67%
|
0.04
|
| Current Accrued Expenses |
|
0.05
-59.92%
|
0.13
-22.52%
|
0.16
+71.34%
|
0.09
|
| Current Debt And Capital Lease Obligation |
|
—
|
10.45
|
—
|
—
|
| Current Debt |
|
—
|
10.45
|
—
|
—
|
| Other Current Borrowings |
|
—
|
10.45
|
—
|
—
|
| Other Current Liabilities |
|
0.20
-77.81%
|
0.90
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Common Stock Equity |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Capital Stock |
|
61.75
+33.88%
|
46.13
+677.29%
|
5.93
|
—
|
| Common Stock |
|
61.75
+33.88%
|
46.13
+677.29%
|
5.93
|
—
|
| Share Issued |
|
0.09
+2435.80%
|
0.00
+5.07%
|
0.00
+0.00%
|
0.00
|
| Ordinary Shares Number |
|
0.09
+2435.80%
|
0.00
+5.07%
|
0.00
+0.00%
|
0.00
|
| Retained Earnings |
|
-56.45
+1.76%
|
-57.46
-812.06%
|
-6.30
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
0.35
-2.73%
|
0.36
+118.35%
|
0.17
|
—
|
| Total Equity Gross Minority Interest |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Total Capitalization |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Working Capital |
|
5.97
+154.34%
|
-10.98
-5376.83%
|
-0.20
-111.79%
|
1.70
|
| Invested Capital |
|
6.72
+1381.23%
|
-0.52
-161.74%
|
-0.20
-111.79%
|
1.70
|
| Total Debt |
|
—
|
10.45
|
—
|
—
|
| Net Debt |
|
—
|
9.71
|
—
|
—
|
| Net Tangible Assets |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Tangible Book Value |
|
6.72
+161.26%
|
-10.97
-5374.09%
|
-0.20
-111.79%
|
1.70
|
| Current Provisions |
|
0.08
+22.35%
|
0.07
|
—
|
—
|
| Financial Assets Designatedas Fair Value Through Profitor Loss Total |
|
0.74
|
0.00
|
—
|
—
|
| Investmentin Financial Assets |
|
0.74
|
0.00
|
—
|
—
|
| Other Equity Interest |
|
1.07
|
—
|
-0.20
-111.80%
|
1.70
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.73
-26.78%
|
-2.95
-85.00%
|
-1.59
-14.01%
|
-1.40
|
| Cash Flow From Continuing Operating Activities |
|
-3.73
-26.78%
|
-2.95
-85.00%
|
-1.59
-14.01%
|
-1.40
|
| Net Income From Continuing Operations |
|
1.01
+101.98%
|
-51.16
-1495.53%
|
-3.21
-72.55%
|
-1.86
|
| Depreciation Amortization Depletion |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Depreciation |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.00
+1678.33%
|
0.00
|
0.00
|
—
|
| Other Non Cash Items |
|
0.22
-99.50%
|
43.58
|
—
|
—
|
| Stock Based Compensation |
|
0.00
-100.00%
|
0.32
+43.65%
|
0.22
-33.36%
|
0.33
|
| Operating Gains Losses |
|
-0.52
-1927.92%
|
0.03
+133.62%
|
-0.08
|
—
|
| Gain Loss On Investment Securities |
|
-0.51
-266.35%
|
0.31
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
-4.06
-174.45%
|
5.46
|
0.00
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.01
-369.40%
|
0.00
+104.33%
|
-0.08
|
—
|
| Change In Working Capital |
|
-0.39
+67.07%
|
-1.17
-179.39%
|
1.48
+1038.80%
|
0.13
|
| Change In Receivables |
|
-0.10
-188.83%
|
0.11
+197.96%
|
-0.11
-209.80%
|
0.10
|
| Change In Prepaid Assets |
|
0.07
+128.70%
|
-0.25
-241.97%
|
-0.07
-56019.30%
|
0.00
|
| Change In Payables And Accrued Expense |
|
-0.36
+65.14%
|
-1.04
-162.41%
|
1.66
+5511.67%
|
0.03
|
| Investing Cash Flow |
|
-0.02
-183.39%
|
-0.01
|
0.00
+100.00%
|
-0.03
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
-183.39%
|
-0.01
|
0.00
+100.00%
|
-0.03
|
| Net PPE Purchase And Sale |
|
-0.01
-72.46%
|
-0.01
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.01
-72.46%
|
-0.01
|
0.00
|
—
|
| Capital Expenditure |
|
-0.01
-72.46%
|
-0.01
|
—
|
—
|
| Gain Loss On Sale Of Business |
|
-0.02
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
-0.01
|
—
|
—
|
-0.03
|
| Financing Cash Flow |
|
9.15
+289.47%
|
2.35
+100.35%
|
1.17
+172.07%
|
-1.63
|
| Cash Flow From Continuing Financing Activities |
|
9.15
+289.47%
|
2.35
+100.35%
|
1.17
+172.07%
|
-1.63
|
| Net Issuance Payments Of Debt |
|
7.41
+215.34%
|
2.35
|
0.00
|
—
|
| Issuance Of Debt |
|
7.41
+196.42%
|
2.50
|
0.00
|
—
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.15
|
0.00
|
—
|
| Long Term Debt Issuance |
|
6.41
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
6.41
|
0.00
|
0.00
|
—
|
| Short Term Debt Issuance |
|
1.00
-60.00%
|
2.50
|
0.00
|
—
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.15
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
1.00
-57.45%
|
2.35
|
0.00
|
—
|
| Net Common Stock Issuance |
|
1.74
|
0.00
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
1.17
+172.07%
|
-1.63
|
| Changes In Cash |
|
5.40
+998.69%
|
-0.60
-43.40%
|
-0.42
+86.28%
|
-3.06
|
| Beginning Cash Position |
|
0.73
-45.05%
|
1.33
-23.90%
|
1.75
-63.55%
|
4.81
|
| End Cash Position |
|
6.14
+736.78%
|
0.73
-45.05%
|
1.33
-23.97%
|
1.76
|
| Free Cash Flow |
|
-3.74
-26.87%
|
-2.95
-85.36%
|
-1.59
-14.01%
|
-1.40
|
| Common Stock Issuance |
|
1.74
|
0.00
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
1.74
|
0.00
|
0.00
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|